Brokerage Firm Rating Update on Exelixis (EXEL)

Exelixis (EXEL) : Zacks Investment Research ranks Exelixis (EXEL) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 5 research analysts is 1.4, which indicates as a Strong Buy.

Exelixis (EXEL) stock is expected to deviate a maximum of $2.31 from the average target price of $10.67 for the short term period. 3 Street Experts have initiated coverage on the stock with the most promising target being $12 and the most muted being $8.


For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Stifel Nicolaus maintains the rating on Exelixis (NASDAQ:EXEL). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $10 per share to $12 per share. The rating by the firm was issued on August 4, 2016.

Exelixis (NASDAQ:EXEL): stock was range-bound between the intraday low of $11.771 and the intraday high of $12.15 after having opened at $11.86 on Wednesdays session. The stock finally closed in the red at $11.86, a loss of -1.32%. The stock remained in the red for the whole trading day. The total traded volume was 3,754,800 shares. The stock failed to cross $12.15 in Wednesdays trading. The stocks closing price on Thursday was $12.08.

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *